Integrated Diagnostics Holdings PLC Final dividend clarification (8200E)
09 Julio 2021 - 10:16AM
UK Regulatory
TIDMIDHC
RNS Number : 8200E
Integrated Diagnostics Holdings PLC
09 July 2021
Integrated Diagnostics Holdings plc
(the "Company")
Final dividend clarification
9 July 2021
(Cairo and London) - In reference to resolution 10 approved by
shareholders at the Annual General Meeting (AGM) of the Company
held on 30 June 2021, the Company notes that the final dividend to
be distributed on 29 July 2021 amounts to US$ 29.1 million in
aggregate for the year ended 31 December 2020 (as previously stated
in the FY2020 and 1Q2021 results announcements issued on 19 May
2021 and 2 June 2021, respectively). This equates to a dividend of
US$ 0.0485 per share (due to an administrative oversight the figure
was rounded to three rather than four decimal places to US$ 0.049
in the AGM Circular and Summary of Proxy Voting documents issued on
7 June 2021 and 30 June 2021, respectively), and is 4% higher than
the US$ 28.0 million in aggregate distributed in the previous
financial year.
-Ends-
About Integrated Diagnostics Holdings (IDH)
IDH is a leading consumer healthcare company in the Middle East
and Africa with operations in Egypt, Jordan, Sudan and Nigeria. The
Group's core brands include Al Borg, Al Borg Scan and Al Mokhtabar
in Egypt, as well as Biolab (Jordan), Ultralab and Al Mokhtabar
Sudan (both in Sudan) and Echo-Lab (Nigeria). A long track record
for quality and safety has earned the Company a trusted reputation,
as well as internationally recognised accreditations for its
portfolio of over 2,000 diagnostics tests. From its base of 483
branches as of 31 March 2021, IDH will continue to add laboratories
through a Hub, Spoke and Spike business model that provides a
scalable platform for efficient expansion. Beyond organic growth,
the Group's expansion plans include acquisitions in new Middle
Eastern, African, and Asian markets where its model is well-suited
to capitalise on similar healthcare and consumer trends and capture
a significant share of fragmented markets. IDH has been a
Jersey-registered entity with a Standard Listing on the Main Market
of the London Stock Exchange (ticker: IDHC) since May 2015 with a
secondary listing on the EGX since May 2021 (ticker: IDHC.CA).
Learn more at idhcorp.com .
The person responsible for arranging the release of this
announcement is Nancy Fahmy, Investor Relations Director at
IDH.
Contact
Nancy Fahmy
Investor Relations Director
T: +20 (0)2 3345 5530 | M: +20 (0)12 2255 7445 |
nancy.fahmy@idhcorp.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
DIVUPUCGMUPGGAB
(END) Dow Jones Newswires
July 09, 2021 11:16 ET (15:16 GMT)
Integrated Diagnostics (LSE:IDHC)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Integrated Diagnostics (LSE:IDHC)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024
